Claims
- 1. A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) an anti-platelet agent and (2) an anti-neoplastic agent and/or radiation therapy.
- 2. A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering an effective amount of Plavix or SR 25909.
- 3. A method of inhibiting or preventing proliferative disease in a patient at increased risk by administering an effective amount of an anti-platelet or anti-clotting agent or SR 25909.
- 4. The method of claim 1, further comprising administering a radiosensitizing agent.
- 5. The method of claim 1 wherein said anti-platelet agent and antineoplastic agent and/or radiation are administered concurrently.
- 6. The method of claim 1 wherein said anti-platelet agent and antineoplastic agent and/or radiation are administered simultaneously.
- 7. The method of claim 1 wherein said anti-platelet agent and antineoplastic agent and/or radiation are administered sequentially.
- 8. The method of claim 1 wherein said antineoplastic agent and/or radiation therapy is administered first.
- 9. The method of claim 1 wherein said anti-platelet agent is administered first.
- 10. The method of claims 1-3 wherein said proliferative disease is selected from the diseases set forth in Table 1.
- 11. The method of claim 1 wherein said antineoplastic agent is selected from the group consisting of Uracil mustard, Chlormethine, Clyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Temozolomide, Methotrexate, 5-Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Gemcitabine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Paclitaxel, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Interferons, Etoposide, Teniposide 17-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estrmustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.
- 12. The method of claim 1 wherein said radiation is ionizing radiation.
- 13. The method of claims 1-3 wherein the anti-platelet or anti-clotting agent is Plavix, Abciximab, Reopro, Fondaparinux Sodium, Arixtra, Argatroban, Novastan, Streptokinase, Streptase, Ticlopidine, Ticlid, Reteplase, Retavase, Alteplase, Activase, Tenecteplase, TNKase, Eptifibatide, Integrilin, Tinzaparin, Innohep, Lepirudin, Refludan, Dalteparin, Fragmin, Dipyridamole, Aggrenox, Antithrombin III Human, Thrombate 3, Anagrelide, Agrylin, Cilostazol, Pletal, Tirofiban, Aggrastat, Pentoxifyline, Trental, Warfarin, Coumadin, Danaparoid, Orgaran, Bivalirudin, Angiomax, Fondaparinux, Organon, Ancrod, Viprinex, Epoprostenol, Flolan, Cangrelor, or Ximelagatran.
- 14. The method of claim 13 wherein the preferred anti-platelet agent is Plavix.
- 15. The method of claim 4 wherein the radiosensitizing agent is Taxotere.
- 16. A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) Plavix and (2) radiation therapy in conjunction with Taxotere.
Parent Case Info
[0001] This Application claims the benefit of U.S. Provisional Application No. 60/433,471, filed Dec. 13, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60433471 |
Dec 2002 |
US |